Industry Projects | Projects by Region | Projects by Category | Archived Projects | Project Gallery
 

Byetta - First-in-Class Incretin Mimetic



Byetta risk factors

Risk factors complications. (Source: ABPI)


Back to Project Details



Related Projects

Ariflo (Cilomilast) - Oral PDE-IV Inhibitor for
Ariflo (cilomilast) is an oral selective phosphodiesterase (PDE) IV...

Capravirine - Anti-Retroviral Drug
Developed by Pfizer Global Research and Development, capravirine is...

Prexige - COX-2 Inhibitor
Prexige (lumiracoxib) is an innovative COX-2 inhibitor developed by...

Erbitux (Cetuximab)
Erbitux is a chimaeric monoclonal antibody (MAb) that is specific for...

Tarceva - Small Molecule
Tarceva (erlotinib) is an oral anti-cancer drug developed by...

See all projects

Related News

Once-Monthly Injectable Exenatide Improves Glucose Control in Study
Amylin Pharmaceuticals, Eli Lilly and Alkermes have reported positive...

See all news

Contact us
Advertise with us
Terms and conditions
Privacy
Links
Newsletter sign up
Online magazine sign up

drugdevelopment-technology.com is a product of Net Resources International. Copyright 2011 Net Resources International, a trading division of SPG Media Limited.